These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8212320)

  • 61. Drug effects on the mechanical properties of large arteries in humans.
    Hope SA; Hughes AD
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):688-93. PubMed ID: 17581231
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
    Lizotte-Waniewski M; Brew K; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutical perspectives for apoptosis modulation in cardiovascular disease.
    Ginghină C; Crăciunescu I; Iorga V
    Rom J Intern Med; 2006; 44(3):213-22. PubMed ID: 18386601
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A multi-endpoint in vivo larval zebrafish (Danio rerio) model for the assessment of integrated cardiovascular function.
    Parker T; Libourel PA; Hetheridge MJ; Cumming RI; Sutcliffe TP; Goonesinghe AC; Ball JS; Owen SF; Chomis Y; Winter MJ
    J Pharmacol Toxicol Methods; 2014; 69(1):30-8. PubMed ID: 24140389
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.
    Zordoky BN; Robertson IM; Dyck JR
    Biochim Biophys Acta; 2015 Jun; 1852(6):1155-77. PubMed ID: 25451966
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Adrenergic receptors in the cardiovascular system (their topography, function and regulation)].
    Korkushko OV; Moroz GZ
    Kardiologiia; 1989 Jul; 29(7):124-8. PubMed ID: 2572717
    [No Abstract]   [Full Text] [Related]  

  • 67. Late-breaking trials at the ACC scientific sessions: insights and controversy.
    Nissen SE
    Curr Cardiol Rep; 2008 Jul; 10(4):247-9. PubMed ID: 18611358
    [No Abstract]   [Full Text] [Related]  

  • 68. Cardiovascular ion channels as a molecular target of flavonoids.
    Scholz EP; Zitron E; Katus HA; Karle CA
    Cardiovasc Ther; 2010 Aug; 28(4):e46-52. PubMed ID: 20633021
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology.
    Salabei JK; Conklin DJ
    Cardiovasc Toxicol; 2013 Sep; 13(3):220-9. PubMed ID: 23408289
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials.
    Liu CL; Guo J; Zhang X; Sukhova GK; Libby P; Shi GP
    Nat Rev Cardiol; 2018 Jun; 15(6):351-370. PubMed ID: 29679024
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Science and clinical practice].
    Chazov EI
    Ter Arkh; 2012; 84(12):5-7. PubMed ID: 23479980
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cardiovascular Pharmacology: An Update and Anesthesia Considerations.
    Asgarian C; Liu H; Kaye AD
    Anesthesiol Clin; 2017 Jun; 35(2):273-284. PubMed ID: 28526148
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 8th International Symposium on Cardiovascular Pharmacotherapy. Amsterdam, The Netherlands. March 28 April 1, 1999. Abstracts.
    Cardiovasc Drugs Ther; 1999 Mar; 13(1):1-86. PubMed ID: 10405623
    [No Abstract]   [Full Text] [Related]  

  • 74. Cardiovascular drug development using radiopharmaceuticals.
    Ukkonen H; Yoshinaga K; DaSilva JN; Beanlands RS; Knuuti J
    Curr Pharm Des; 2009; 15(9):935-42. PubMed ID: 19275657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of centrally active cardiovascular agents in cognitive disorders.
    Theobald RJ
    Curr Opin Pharmacol; 2017 Apr; 33():70-75. PubMed ID: 28587973
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Potential Role of Creatine in Vascular Health.
    Clarke H; Hickner RC; Ormsbee MJ
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33807747
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Statistical challenges in a regulatory review of cardiovascular and CNS clinical trials.
    Hung HM; Wang SJ; Yang P; Jin K; Lawrence J; Kordzakhia G; Massie T
    J Biopharm Stat; 2016; 26(1):37-43. PubMed ID: 26366624
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bibliography. Current world literature. Clinical trials.
    Curr Opin Cardiol; 2008 Jul; 23(4):407-21. PubMed ID: 18520727
    [No Abstract]   [Full Text] [Related]  

  • 79. Cardiovascular therapeutics.
    Shakur R; Cockrum E; Scott D
    Br J Hosp Med (Lond); 2008 Sep; 69(9):M136-40. PubMed ID: 18819300
    [No Abstract]   [Full Text] [Related]  

  • 80. Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers.
    Oddie CJ; Dilley RJ; Bobik A
    Clin Exp Pharmacol Physiol; 1992 May; 19(5):392-5. PubMed ID: 1387843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.